Phase II study of continuation maintenance by use of TS1 and Bevacizumab after induction chemotherapy of cisplatin and TS1 pulse bevacizumab in patients with Stage IIIB / IV non-squamous and non-small cell lung cancer - Research of efficacy predictive biomarker
Phase of Trial: Phase II
Latest Information Update: 18 May 2018
At a glance
- Drugs Bevacizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Cisplatin
- Indications Lung cancer; Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 11 May 2018 Planned End Date changed from 1 Mar 2016 to 31 Mar 2020.
- 11 May 2018 Status changed from recruiting to suspended.
- 12 Feb 2013 New trial record